Rai M K
Junior Resident, Department of Pathology, Rajendra Institute of Medical Sciences , Ranchi, India .
Junior Resident, Professor and HOD, Department of Pathology, Rajendra Institute of Medical Sciences , Ranchi, India .
J Clin Diagn Res. 2016 Apr;10(4):EC06-9. doi: 10.7860/JCDR/2016/15738.7561. Epub 2016 Apr 1.
Breast tumours are classified as benign, proliferative and invasive tumours. Estrogen hormone influences the proliferative activity and progression of the tumour. Estrogen Receptor (ER) status and proliferative index (Ki 67) are important histopathological factors in the development and prognosis of these tumours.
The present study was aimed to evaluate the variations in ER and Ki-67 expression in three broad categories of breast lesions namely benign breast disease, proliferative breast disease and malignant breast disease.
ER% and Ki-67% was evaluated on the histopathological tissues of 15 patients each of benign, proliferative and invasive breast tumours. The ER+/ Ki-67± ratio was calculated and the variation of expression between the three categories was analyzed using student's t-test. Pearson's coefficient of correlation was used to correlate ER and Ki-67 positivity within each category.
The mean ER+/Ki-67+ in benign, proliferative and invasive tumours was 0.81, 0.87 and 1.42 respectively. A statistically significant difference in ER+/Ki-67+ proportions was observed between proliferative breast disease category and malignant breast disease category and also between benign breast disease category and malignant breast disease category (p<0.05). However, no significant difference was observed in benign breast disease category and proliferative breast disease category (p>0.05). A significant correlation was observed in proliferative breast disease and malignant breast disease categories. However, no significant correlation was observed in benign breast disease category.
ER+/Ki-67+ ratio is an important determinant of the invasive breast cancer and can be used to differentiate invasive cancers from benign and proliferative breast tumours.
乳腺肿瘤分为良性、增殖性和浸润性肿瘤。雌激素会影响肿瘤的增殖活性和进展。雌激素受体（ER）状态和增殖指数（Ki 67）是这些肿瘤发生发展及预后的重要组织病理学因素。
本研究旨在评估雌激素受体（ER）和Ki-67在三类乳腺病变（即良性乳腺疾病、增殖性乳腺疾病和恶性乳腺疾病）中的表达差异。
对15例良性、增殖性和浸润性乳腺肿瘤患者的组织病理学样本进行ER%和Ki-67%评估。计算ER+/Ki-67±比值，并使用学生t检验分析这三类病变之间的表达差异。采用Pearson相关系数分析每类病变中ER与Ki-67阳性之间的相关性。
良性、增殖性和浸润性肿瘤的平均ER+/Ki-67+分别为0.81、0.87和1.42。增殖性乳腺疾病与恶性乳腺疾病之间以及良性乳腺疾病与恶性乳腺疾病之间的ER+/Ki-67+比例存在统计学显著差异（p<0.05）。然而，良性乳腺疾病与增殖性乳腺疾病之间未观察到显著差异（p>0.05）。增殖性乳腺疾病和恶性乳腺疾病类别中观察到显著相关性。然而，良性乳腺疾病类别中未观察到显著相关性。
ER+/Ki-67+比值是浸润性乳腺癌的重要决定因素，可用于区分浸润性癌与良性和增殖性乳腺肿瘤。
